search
Back to results

Effect of Photodynamic Therapy on Skin Microbiome. Single Center Study (PHOMIC-III)

Primary Purpose

Prosthesis and Implants, Surgical Site Infection, Prosthetic Joint Infection

Status
Recruiting
Phase
Early Phase 1
Locations
Switzerland
Study Type
Interventional
Intervention
Photodynamic Therapy
Sponsored by
University of Zurich
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Prosthesis and Implants

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Healthy male and female participants ≥ 18 years who volunteer for the pilot study, in which a routine photodynamic treatment at the Department of Dermatology will be performed and effect of skin colonization will be analyzed, and who signed an informed consent (after information about the project) Exclusion Criteria: Pregnant and breastfeeding women Participants with inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc., Participants taking antibiotics in the 14 days prior to PDT or until follow-up at 21 days Participants who received oral retinoid therapy within the last 6 months Participants who received anti-inflammatory agents as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) within the 14 days prior and after the PDT Participants taking any photosensitizing drugs within 4 weeks prior to PDT Participants who had a history of photosensitivity disorder Fitzpatrick's skin phototype V-VI

Sites / Locations

  • University Hospital of ZurichRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

PDT group

Arm Description

PDT with 5% topical methyl aminolevulinate (MAL) before skin antisepsis

Outcomes

Primary Outcome Measures

Culture results of skin swabs
Quantitative evaluation of bacterial density and species from skin swabs taken before PDT, immediately after PDT, and after after skin antisepsis using culture technique

Secondary Outcome Measures

Full Information

First Posted
December 22, 2022
Last Updated
May 23, 2023
Sponsor
University of Zurich
search

1. Study Identification

Unique Protocol Identification Number
NCT05676801
Brief Title
Effect of Photodynamic Therapy on Skin Microbiome. Single Center Study (PHOMIC-III)
Official Title
Effects of Photodynamic Therapy on the Human Inguinal Skin Microbiome to Improve Antiseptic Effect - Pilot 3
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 4, 2023 (Actual)
Primary Completion Date
September 1, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Zurich

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The overarching aim of this research project is to prevent orthopedic implant-associated infections. This study aims to investigate if PDT has an effect on bacterial skin colonization in order to improve skin antisepsis strategies for the prevention of surgical site infections.
Detailed Description
Periprosthetic joint infections are a feared complication after orthopedic surgery in particular in our increasing elderly population. These infections are usually difficult to treat, because microorganisms persist in biofilms on the orthopedic implant surface. Therefore, it would be desirable to prevent these infections. It is hypothesized that bacteria from the skin surface or dermis - such as Staphylococcus aureus, coagulase-negative staphylococci, or Cutibacterium sp. - are transmitted into the periimplant tissue during surgery. In an interdisciplinary study with the Orthopedic University Hospital Balgrist, the investigators see that common skin antisepsis preparation is not effective to eliminate skin bacteria before surgery because they might persist in sebaceous or sweat glands. Photodynamic therapy (PDT) has the potential to improve skin antisepsis as we recently showed. The PDT works here on the one hand through a long-lasting destruction of the sebaceous glands, and on the other hand due to anti-inflammatory and bactericidal effects. In a previous pilot study, the investigators tested if skin antisepsis can be improved with previous PDT using the photosensitizer-inducing prodrug 5% topical methyl aminolevulinate (MAL) on inguinal skin in 10 healthy participants. The induced photosensitizer was protoporphyrin IX (Pp IX) activated by red light (633 nm). The investigators showed 100% killing of colonizing skin bacteria at the same day after this treatment. However, orthopedic surgeons are hesitant to perform an arthroplasty surgery after such a treatment due to the side effects of skin erythema for a few days. In a follow up study, the investigators tested the PDT effect using 5-aminolevulinic acid (5-ALA) induced Pp IX with a daylight lamp (400-750nm) and achieved 70% skin sterility with skin redness only in a minority of participants. The sterilizing effect lasted up to 3 days. The investigators are entirely convinced about this novel prevention concept using daylight but need to identify the photosensitizer with the ideal balance of bactericidal effect versus skin irritation. Building upon the gathered data, the investigators will explore PDT with longer incubation time of the photosensitizer MAL and the less toxic and pain free illumination with daylight. Primary outcome: Effect of photodynamic therapy with the photosensitizer Pp IX (MAL) and daylight in combination with surgical skin antisepsis on bacterial skin colonization on the day of application and on day 3 after PDT.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prosthesis and Implants, Surgical Site Infection, Prosthetic Joint Infection, Postoperative Wound Infection Deep Incisional Surgical Site

7. Study Design

Primary Purpose
Prevention
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Model Description
All patients get Photodynamic treatment in addition to skin antisepsis. (The contrallateral side of the leg is our control side, therefore only one arm)
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PDT group
Arm Type
Experimental
Arm Description
PDT with 5% topical methyl aminolevulinate (MAL) before skin antisepsis
Intervention Type
Drug
Intervention Name(s)
Photodynamic Therapy
Intervention Description
PDT with methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX
Primary Outcome Measure Information:
Title
Culture results of skin swabs
Description
Quantitative evaluation of bacterial density and species from skin swabs taken before PDT, immediately after PDT, and after after skin antisepsis using culture technique
Time Frame
within 10 days after PDT

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male and female participants ≥ 18 years who volunteer for the pilot study, in which a routine photodynamic treatment at the Department of Dermatology will be performed and effect of skin colonization will be analyzed, and who signed an informed consent (after information about the project) Exclusion Criteria: Pregnant and breastfeeding women Participants with inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc., Participants taking antibiotics in the 14 days prior to PDT or until follow-up at 21 days Participants who received oral retinoid therapy within the last 6 months Participants who received anti-inflammatory agents as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) within the 14 days prior and after the PDT Participants taking any photosensitizing drugs within 4 weeks prior to PDT Participants who had a history of photosensitivity disorder Fitzpatrick's skin phototype V-VI
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yvonne Achermann, PD Dr. med.
Phone
+41 44 396 74 18
Email
yvonne.achermann@usz.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yvonne Achermann, PD Dr. med.
Organizational Affiliation
Dermatology
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital of Zurich
City
Zurich
ZIP/Postal Code
8091
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yvonne Achermann
Phone
+41 44 396 74 18
Email
yvonne.achermann@usz.ch

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Effect of Photodynamic Therapy on Skin Microbiome. Single Center Study (PHOMIC-III)

We'll reach out to this number within 24 hrs